Septa Pharmaceuticals Inc. announces it has successfully acquired CeeNU® (lomustine) from Bristol Myers Squibb Canada, with the transaction effective June 29, 2026. The company says the acquisition is part of its growth in the Canadian healthcare sector and positions Septa to obtain rights to the CeeNU® product in Canada. The announcement is issued from Mississauga, Ontario, on July 15, 2026, in materials distributed by PR Newswire in multiple languages.
Across the sources, the key points are consistent: Septa is the acquiring party; Bristol Myers Squibb Canada is the seller; the product is CeeNU® (lomustine); and the acquisition becomes effective on June 29, 2026. The releases do not provide additional detail in the excerpts provided on financial terms, regulatory approvals, supply arrangements, or changes to distribution or manufacturing. The information is presented as a completed acquisition effective as of the stated date.
